SeaStar Medical Holding Co. (NASDAQ:ICU) Sees Significant Increase in Short Interest

SeaStar Medical Holding Co. (NASDAQ:ICU) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 357,600 shares, an increase of 18.8% from the February 13th total of 300,900 shares. Approximately 4.2% of the company’s shares are short sold. Based on an average trading volume of 421,900 shares, the short-interest ratio is currently 0.8 days.

SeaStar Medical Stock Up 0.5 %

Shares of NASDAQ ICU traded up $0.01 during midday trading on Tuesday, reaching $2.18. The company had a trading volume of 106,467 shares, compared to its average volume of 246,017. SeaStar Medical has a one year low of $1.50 and a one year high of $22.00. The firm’s fifty day moving average price is $1.83 and its 200-day moving average price is $2.75. The stock has a market cap of $14.11 million, a PE ratio of -0.19 and a beta of -0.97.

Institutional Investors Weigh In On SeaStar Medical

An institutional investor recently raised its position in SeaStar Medical stock. Geode Capital Management LLC grew its holdings in SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 45,430 shares of the company’s stock after buying an additional 5,618 shares during the quarter. Geode Capital Management LLC owned approximately 1.02% of SeaStar Medical worth $88,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.69% of the company’s stock.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.